VA-FLIR-SYSTEMS
7.1.2020 13:02:06 CET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) and ANSYS (NASDAQ: ANSS) are collaborating to deliver superior hazard detection capabilities for assisted driving and autonomous vehicles (AVs) — empowering automakers to deliver unprecedented vehicle safety. Through this collaboration, FLIR will integrate a fully physics-based thermal sensor into ANSYS’ leading-edge driving simulator to model, test, and validate thermal camera designs within an ultra-realistic virtual world. The new solution will reduce original equipment manufacturers’ (OEM) development time by optimizing thermal camera placement for use with tools such as automatic emergency braking (AEB), pedestrian detection, and within future AVs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005299/en/
Having the ability to test in virtual environments complements the existing systems available to FLIR customers and partners, including the FLIR automotive development kit (ADK™) featuring a FLIR Boson® thermal camera, the FLIR starter thermal dataset and the regional, city-specific thermal datasets. The FLIR thermal dataset programs were created for machine learning in advanced driver assistance development (ADAS), AEB, and AV systems.
The current AV and ADAS sensors face challenges in darkness or shadows, sun glare and inclement weather such as most fog. Thermal cameras, however, can effectively detect and classify objects in these conditions. Integrating FLIR Systems’ thermal sensor into ANSYS® VRXPERIENCE® enables simulation of thousands of driving scenarios across millions of miles in mere days. Furthermore, engineers can simulate difficult-to-produce scenarios where thermal provides critical data, including detecting pedestrians in crowded, low-contrast environments.
“By adding ANSYS’ industry-leading simulation solutions to the existing suite of tools for physical testing, engineers, automakers, and automotive suppliers can improve the safety of vehicles in all types of driving conditions,” said Frank Pennisi, President of the Industrial Business Unit at FLIR Systems. “The industry can also recreate corner cases that drivers can see every day but are difficult to replicate in physical environments, paving the way for improved neural networks and the performance of safety features such as AEB.”
“FLIR Systems’ recognizes the limitations of relying solely on gathering machine learning datasets in the physical world to make automotive thermal cameras as safe and reliable as possible for automotive uses,” said Eric Bantegnie, Vice president and General Manager at ANSYS. “Now with ANSYS solutions, FLIR can further empower automakers to speed the creation and certification of assisted-driving systems with thermal cameras.”
In addition to the city-specific data sets, FLIR has more than a decade of experience in the automotive industry. FLIR has provided more than 700,000 thermal sensors as part of its night vision warning systems for a variety of carmakers, including GM, Audi and Mercedes-Benz. Also, FLIR recently announced that its thermal sensor has been selected by Veoneer, a tier-one automotive supplier, for its level-four AV production contract with a top global automaker, planned for 2021.
FLIR Systems’ thermal-enhanced demonstration car, along with other innovative FLIR products, will be on display at the FLIR booth #8528 during the 2020 Consumer Electronics Show in Las Vegas, Nevada from January 6 - 10.
For more information on FLIR Systems’ automotive solutions, please visit https://www.flir.com/safercars .
About FLIR Systems, Inc.
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense, industrial, and commercial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense," creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005299/en/
Contact:
Media Contact: Tim McDowd (503) 498-3146 Tim.McDowd@flir.com
Investor Relations: Lasse Glassen Addo Investor Relations Phone: 424-238-6249 Email: lglassen@addoir.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
